Jaguar Health Inc (JAGX)

$0.85 -0.02 (-1.87%)
Market Cap 2.73M
Revenue (ttm) 11.69M
Net Income (ttm) -38.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -329.26%
Debt to Equity Ratio 1.75
Volume 369,131
Avg Vol 4,492,758
Day's Range N/A - N/A
Shares Out 3.74M
Stochastic %K 91%
Beta 0.09
Analysts Hold
Price Target $16.00

Company Profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infe...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 371 8300
Address:
200 Pine Street, Suite 400, San Francisco, United States
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:59 PM
$JAGX https://jaguarhealth.gcs-web.com/node/15796/html
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:57 PM
$JAGX
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:55 PM
$JAGX fraud is very possible here as the shares are uncertificated. Any joe blow can say they are redeeming these securities, but nothing can tie them to the owner. Good time for fife to use another one of his alias'.
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:51 PM
$JAGX they are giving 3 sceneros. $0.10 warants $0.60 warants or never in a million years $1.50 warrants to pay John M Fifes $34M debt off. He need not pay any money out of pocket for these shares, as its monies owed him. Why all the whoopla, i dunno? Just dont get too excited.
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:45 PM
$JAGX
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:43 PM
$JAGX
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 9:21 PM
$JAGX Tomorrow kaboom up than 1 dollar
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 9:19 PM
$JAGX It is not absolute 👇
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:16 PM
$JAGX Uncertificated Shares. The shares of Series O Preferred Stock shall be uncertificated. Optional Conversion At any time prior to December 31, 2026, the Company may, in its sole discretion. 300,000,000 shares incoming.
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 8:57 PM
$JAGX No bad day
0 · Reply
Latest News on JAGX
Jaguar Health Announces a Special One-time Stock Dividend

Feb 18, 2026, 9:00 AM EST - 8 days ago

Jaguar Health Announces a Special One-time Stock Dividend

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jan 22, 2026, 9:00 AM EST - 5 weeks ago

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

Jan 14, 2026, 9:00 AM EST - 6 weeks ago

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Jan 12, 2026, 9:00 AM EST - 6 weeks ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Jan 6, 2026, 9:00 AM EST - 7 weeks ago

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jan 2, 2026, 9:00 AM EST - 7 weeks ago

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Dec 15, 2025, 9:00 AM EST - 2 months ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Dec 10, 2025, 9:00 AM EST - 2 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

Dec 8, 2025, 4:15 PM EST - 2 months ago

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Dec 2, 2025, 9:00 AM EST - 3 months ago

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

Nov 24, 2025, 9:00 AM EST - 3 months ago

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

Nov 20, 2025, 9:00 AM EST - 3 months ago

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript

Nov 17, 2025, 10:17 AM EST - 3 months ago

Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

Nov 17, 2025, 8:00 AM EST - 3 months ago

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

Nov 14, 2025, 9:00 AM EST - 3 months ago

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

Nov 13, 2025, 9:00 AM EST - 3 months ago

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

Nov 6, 2025, 9:00 AM EST - 4 months ago

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 24, 2025, 4:15 PM EDT - 4 months ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

Oct 6, 2025, 9:00 AM EDT - 5 months ago

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

Sep 30, 2025, 9:00 AM EDT - 5 months ago

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Sep 25, 2025, 9:00 AM EDT - 5 months ago

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

Sep 24, 2025, 9:00 AM EDT - 5 months ago

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

Sep 23, 2025, 9:00 AM EDT - 5 months ago

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

Sep 5, 2025, 9:00 AM EDT - 6 months ago

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Aug 21, 2025, 9:00 AM EDT - 6 months ago

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

Aug 19, 2025, 4:15 PM EDT - 6 months ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

Jaguar Health, Inc. (JAGX) Q2 2025 Earnings Call Transcript

Aug 19, 2025, 3:43 PM EDT - 6 months ago

Jaguar Health, Inc. (JAGX) Q2 2025 Earnings Call Transcript

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

Aug 19, 2025, 9:00 AM EDT - 6 months ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

Aug 14, 2025, 8:00 AM EDT - 7 months ago

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Aug 12, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jul 10, 2025, 8:30 AM EDT - 8 months ago

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Jul 8, 2025, 9:00 AM EDT - 8 months ago

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jun 30, 2025, 9:00 AM EDT - 8 months ago

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jun 26, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jun 25, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jun 24, 2025, 4:15 PM EDT - 8 months ago

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Jun 23, 2025, 9:00 AM EDT - 8 months ago

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Jun 17, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jun 11, 2025, 10:00 AM EDT - 9 months ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

Jun 9, 2025, 4:15 PM EDT - 9 months ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

Jun 9, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series

Jun 6, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 21, 2025, 8:00 AM EDT - 10 months ago

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

May 20, 2025, 9:15 AM EDT - 10 months ago

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript

May 15, 2025, 8:43 PM EDT - 10 months ago

Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript

Jaguar Health Reports First Quarter 2025 Financials

May 15, 2025, 2:30 PM EDT - 10 months ago

Jaguar Health Reports First Quarter 2025 Financials

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

May 14, 2025, 9:00 AM EDT - 10 months ago

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

May 8, 2025, 9:30 AM EDT - 10 months ago

Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

May 7, 2025, 9:15 AM EDT - 10 months ago

Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

Apr 30, 2025, 8:15 AM EDT - 10 months ago

Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:59 PM
$JAGX https://jaguarhealth.gcs-web.com/node/15796/html
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:57 PM
$JAGX
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:55 PM
$JAGX fraud is very possible here as the shares are uncertificated. Any joe blow can say they are redeeming these securities, but nothing can tie them to the owner. Good time for fife to use another one of his alias'.
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:51 PM
$JAGX they are giving 3 sceneros. $0.10 warants $0.60 warants or never in a million years $1.50 warrants to pay John M Fifes $34M debt off. He need not pay any money out of pocket for these shares, as its monies owed him. Why all the whoopla, i dunno? Just dont get too excited.
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:45 PM
$JAGX
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:43 PM
$JAGX
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 9:21 PM
$JAGX Tomorrow kaboom up than 1 dollar
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 9:19 PM
$JAGX It is not absolute 👇
0 · Reply
MarketManStockWizzard
MarketManStockWizzard Feb. 26 at 9:16 PM
$JAGX Uncertificated Shares. The shares of Series O Preferred Stock shall be uncertificated. Optional Conversion At any time prior to December 31, 2026, the Company may, in its sole discretion. 300,000,000 shares incoming.
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 8:57 PM
$JAGX No bad day
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 8:51 PM
$JAGX SSR tomorrow with 240,000 shares short pending to cover
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 6:58 PM
$JAGX It's consolidating all day at 0.81s. It will break out before the end of today's session to above 0.90.
0 · Reply
andycoolbeans
andycoolbeans Feb. 26 at 5:51 PM
$JAGX only 283k traded so far 1250pm
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 2:56 PM
$JAGX 286,000 shares short pending to cover SSR day
0 · Reply
andycoolbeans
andycoolbeans Feb. 26 at 2:50 PM
$JAGX hope people got some shares. All the way down to .75
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 2:42 PM
$JAGX will to explode today
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 2:37 PM
$JAGX ssr already buy shares
0 · Reply
andycoolbeans
andycoolbeans Feb. 26 at 2:01 PM
$JAGX don’t forget https://m.youtube.com/watch?v=f61xKTB2btg
0 · Reply
andycoolbeans
andycoolbeans Feb. 26 at 1:58 PM
$AG the day and the swing traders - take a look at $JAGX Preferred shares offer ends on Monday so should get a nice bounce here. A lot of toxicity around this company but it sounds like with new deals and increased capital they could actually get their act together Analyst price target: $7
0 · Reply
Torobravo_1
Torobravo_1 Feb. 26 at 1:11 PM
$JAGX Short Interest 386,035 shares - source: NASDAQ Short Interest Ratio 0.88 Days to Cover Short Interest % Float 12.19 % According to what came out today, the float is about 3.2 million kaboom up anytime now
0 · Reply
Omago78
Omago78 Feb. 26 at 1:01 PM
$JAGX These retards will unfortunitly not listen.
1 · Reply